• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

41.10 +1.85 (+4.71%)
Official Closing Price Updated: 4:10 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Today 7:00 EDT
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
October 02, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
October 02, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
September 30, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
September 28, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Releases Q3 2026 Aide Memoire
September 23, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
September 23, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
September 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
September 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
September 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
September 16, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
September 14, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
September 10, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Launch of Offering of Senior Notes
September 07, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
September 04, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
September 02, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
September 01, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
August 31, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
August 28, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
August 19, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
August 11, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
July 29, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
July 09, 2026
From Polpharma Biologics International AG
Via Business Wire
News headline image
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
July 09, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
July 07, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Releases Q2 2026 Aide Memoire
June 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
June 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
June 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
June 10, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
June 08, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap